SCHEMBL15469442

SCHEMBL15469442

Cc1ccc([C@@]2(NC(=O)Nc3cccc(F)c3)CCOc3cccnc32)cc1

nearest known ligand 0.47

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ NPC1 O15118 10/20 0.47
▸ RAB9A P51151 10/20 0.47
▸ L3MBTL1 Q9Y468 1/20 0.47
▸ SMN1; SMN2 Q16637 3/20 0.44
▸ TP53 P04637 1/20 0.44
▸ NFKB1 P19838 1/20 0.44
▸ NFKB2 Q00653 1/20 0.44
▸ RELA Q04206 1/20 0.44
▸ TRPM8 Q7Z2W7 1/20 0.44
▸ KMT2A Q03164 4/20 0.44
▸ POLB P06746 1/20 0.44
▸ LMNA P02545 2/20 0.42
▸ CYP1A2 P05177 1/20 0.42
▸ CYP2C9 P11712 1/20 0.42
▸ CYP2C19 P33261 1/20 0.42
▸ MEN1 O00255 2/20 0.41
▸ GBA1 P04062 1/20 0.41
▸ TAAR1 Q96RJ0 1/20 0.41
▸ MAOB P27338 1/20 0.40
▸ CASP3 P42574 1/20 0.40

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL15467600 0.90 MTOR (0.48) NPC1RAB9AL3MBTL1SMN1; SMN2TP53
SCHEMBL15467601 0.90 MTOR (0.48) NPC1RAB9AL3MBTL1SMN1; SMN2TP53
SCHEMBL15469445 0.90 RAB9A (0.44) NPC1RAB9AL3MBTL1SMN1; SMN2TP53
SCHEMBL15469443 0.86 NPC1 (0.50) NPC1RAB9ASMN1; SMN2TP53TRPM8
SCHEMBL16418681 0.81 TRPM8 (0.41) NPC1RAB9ASMN1; SMN2TP53NFKB1
SCHEMBL15469370 0.80 TRPM8 (0.55) NPC1RAB9AL3MBTL1TRPM8KMT2A
SCHEMBL15467437 0.80 TRPM8 (0.46) NPC1RAB9ATRPM8
SCHEMBL15467435 0.80 TRPM8 (0.46) NPC1RAB9ATRPM8
SCHEMBL16418662 0.80 TRPM8 (0.43) NPC1RAB9ATRPM8KMT2ALMNA
SCHEMBL16418655 0.79 TRPM8 (0.41) NPC1RAB9ASMN1; SMN2TP53TRPM8

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8952009-B2 Chroman derivatives as TRPM8 inhibitors AMGEN INC. (US) 2015-02-10 — — US disclosed
US-20150031668-A1 CHROMAN DERIVATIVES AS TRPM8 INHIBITORS AMGEN INC (US) 2015-01-29 — — US disclosed
US-20140045855-A1 CHROMAN DERIVATIVES AS TRPM8 INHIBITORS AMGEN INC. (US) 2014-02-13 — — US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20150031668-A1 CHROMAN DERIVATIVES AS TRPM8 INHIBITORS TRPM8, TRPM5, TRPM7 NPC1 702/4885RAB9A 1056/4885L3MBTL1 4745/4885
US-20140045855-A1 CHROMAN DERIVATIVES AS TRPM8 INHIBITORS TRPM8, TRPM5, TRPM7 NPC1 702/4885RAB9A 1056/4885L3MBTL1 4745/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback